Patents by Inventor Judy Young

Judy Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTI-CMET ANTAGONISTS
    Publication number: 20140227258
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: March 14, 2014
    Publication date: August 14, 2014
    Applicant: Genentech, Inc.
    Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • ANTI-CMET ANTAGONISTS
    Publication number: 20120082663
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: July 28, 2011
    Publication date: April 5, 2012
    Applicant: Genentech, Inc.
    Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • ANTI-CMET ANTAGONISTS
    Publication number: 20120082662
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: July 28, 2011
    Publication date: April 5, 2012
    Applicant: Genentech, Inc.
    Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • ANTI-CMET ANTAGONISTS
    Publication number: 20110300146
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: January 18, 2011
    Publication date: December 8, 2011
    Applicant: Genentech, Inc.
    Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • BIOLOGICAL MARKERS PREDICTIVE OF RHEUMATOID ARTHRITIS RESPONSE TO LYMPHOTOXIN ANTAGONISTS
    Publication number: 20110263451
    Abstract: The present invention relates to a soluble lymphotoxin (solLT) and methods of using the solLT as a biomarker in the treatment of autoimmune disease. More particularly, the present invention relates to soluble lymphotoxin alpha-beta (solLT??) and methods of using this solLT?? as a biomarker in the treatment of rheumatoid arthritis (RA).
    Type: Application
    Filed: September 29, 2009
    Publication date: October 27, 2011
    Inventors: Jane Grogan, Wai Lee Wong, Judy Young
  • Anti-cmet antibodies
    Patent number: 7892550
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: February 22, 2011
    Assignee: Genentech, Inc.
    Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • Humanized anti-cmet antibodies
    Patent number: 7476724
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: January 13, 2009
    Assignee: Genentech, Inc.
    Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • Humanized Anti-CMET Antagonists
    Publication number: 20070092520
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: October 2, 2006
    Publication date: April 26, 2007
    Applicant: Genentech, Inc.
    Inventors: Mark Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • Humanized anti-cmet antagonists
    Publication number: 20060134104
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: August 4, 2005
    Publication date: June 22, 2006
    Applicant: Genentech, Inc.
    Inventors: Mark Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • Methods for use of MPL ligands with primitive human stem cells
    Publication number: 20060024275
    Abstract: Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations (CD34+Lin?, CD34+Thy-1+Lin?, and CD34+Lin? Rh123?lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.
    Type: Application
    Filed: July 1, 2005
    Publication date: February 2, 2006
    Inventors: Lesley Murray, Judy Young